Replicor to disclose interim REP 2055 / 2139 clinical efficacy data in patients with chronic hepatitis B at the 14th International Symposium of Viral Hepatitis and Liver Disease (ISVHLD 2012).
22-25 June 2012, Shanghai International Convention Center, Shanghai, China.
June 22nd, 2012 – Replicor will disclose updated interim results and metadata analysis of antiviral responses in patients with chronic hepatitis B who are enrolled in its proof of concept clinical trials of REP 2055 and REP 2139 for the treatment of chronic hepatitis B at the 14th International Symposium of Viral Hepatitis and Liver Disease (ISVHLD 2012) currently being held from 22-25th of June. This important meeting, held only once every three years, is the preeminent meeting focusing on viral hepatitis and attracts key academicians and physicians working to improve the treatment outlook for patients with viral hepatitis.
REP 2139 represents the latest clinical candidate in a new class of antiviral agents, nucleic acid polymers (or NAPs) that block the release of hepatitis B surface antigen (HBsAg) which has been associated with HBV-specific immune defects and may contribute to the long term persistence of HBV infection in the liver. Metadata analysis of patients on REP 2055 or REP 2139 demonstrates that serum HBsAg can be routinely eliminated in 12-16 weeks and is followed by a restoration in the patient’s immune response, resulting in a substantial elimination of virus from the blood of patients. Replicor will present updated clinical efficacy results and metadata analysis of antiviral responses in patients receiving REP 2055 or REP 2139 in an oral presentation on Sunday June 24th, 2012.